Adverum Biotechnologies, Inc.
ADVM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1,000 | $3,600 | $0 | $7,500 |
| % Growth | -72.2% | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $1,000 | $3,600 | $0 | $7,500 |
| % Margin | 100% | 100% | – | 100% |
| R&D Expenses | $77,041 | $77,486 | $99,277 | $89,181 |
| G&A Expenses | $63,118 | $55,056 | $57,858 | $64,441 |
| SG&A Expenses | $63,118 | $55,056 | $57,858 | $64,441 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $140,159 | $132,542 | $157,135 | $153,622 |
| Operating Income | -$139,159 | -$128,942 | -$157,135 | -$146,122 |
| % Margin | -13,915.9% | -3,581.7% | – | -1,948.3% |
| Other Income/Exp. Net | $8,232 | $5,748 | $2,673 | $582 |
| Pre-Tax Income | -$130,927 | -$123,194 | -$154,462 | -$145,540 |
| Tax Expense | $0 | -$1,078 | $74 | $0 |
| Net Income | -$130,927 | -$122,116 | -$154,536 | -$145,540 |
| % Margin | -13,092.7% | -3,392.1% | – | -1,940.5% |
| EPS | -6.62 | -2.02 | -2.67 | -1.48 |
| % Growth | -227.7% | 24.3% | -80.4% | – |
| EPS Diluted | -6.62 | -2.02 | -2.67 | -1.48 |
| Weighted Avg Shares Out | 19,782 | 57,977 | 57,977 | 98,361 |
| Weighted Avg Shares Out Dil | 19,782 | 57,977 | 57,977 | 98,361 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3,653 | $5,644 | $6,528 | $4,645 |
| EBITDA | -$135,506 | -$123,298 | -$150,607 | -$141,477 |
| % Margin | -13,550.6% | -3,424.9% | – | -1,886.4% |